Gold prices set for weekly drop as strong dollar weighs; Trump tariffs in focus
In a challenging year for AIT Therapeutics (NASDAQ:XAIR), the company’s stock has plummeted to a 52-week low, touching a price level of just $0.24, with market capitalization shrinking to approximately $20 million. This significant downturn reflects a staggering 1-year decline of -85%, though InvestingPro analysis suggests the stock is currently undervalued. Analyst price targets range from $1 to $5, indicating potential recovery opportunities despite the current weakness. Investors have watched with concern as the stock struggled to find its footing amidst market pressures and internal challenges, leading to this new low point. The company, known for its innovative approach in the medical field, now faces the arduous task of regaining investor confidence and reversing the negative trend. While current financial health scores indicate weakness, analysts project significant revenue growth of over 348% for the current fiscal year. For deeper insights into AIT Therapeutics’ valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Beyond Air reported a significant increase in revenue for the third fiscal quarter of 2025, reaching $1.072 million, which exceeded analyst forecasts. This marks a 34% increase from the previous quarter and a 175% year-over-year growth, attributed to the commercial success of its LungFit PH system. Beyond Air’s net loss improved to $0.15 per share from $0.50 per share the previous year, showcasing better financial management. The company has also expanded its global distribution network for LungFit PH, now spanning 18 countries, following CE Mark approval. Beyond Air announced a $35 million at-the-market equity offering with BTIG, LLC, with the potential to sell up to $9.892 million based on current public float. Additionally, BTIG reiterated a Neutral rating for Beyond Air, maintaining a cautious stance while recognizing the company’s strategic initiatives. Beyond Air plans to provide further revenue guidance during the fourth fiscal quarter earnings call in June. Lastly, NeuroNOS, a subsidiary of Beyond Air, made a breakthrough in Alzheimer’s disease research, potentially opening new therapeutic avenues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.